Our client investigates why the same medication can produce different levels of drug exposure across patient populations. She earned her Ph.D. in biopharmaceutics and pharmacokinetics at Hacettepe University, studying how malnutrition affects drug absorption and permeability. Her research experience subsequently included work at the University of Limoges in France and a visiting scholar appointment at the University at Buffalo. She later joined a US-based pharmaceutical research company remotely as a postdoctoral pharmacometrician, applying quantitative methods to preclinical and clinical study data.
Our firm presented her experimental research, computational expertise, and pharmaceutical industry experience as the foundation for her proposed work. The petition included peer-reviewed publications, research funding, and evidence of her contributions to pharmacokinetic modeling. We explained how her plans to quantify the effects of disease, nutritional status, and patient variability could inform dose selection, improve clinical trial design, and strengthen analyses prepared for regulatory submissions.
Her work in France provided a concrete example of the patient needs behind these methods: characterizing drug exposure in pediatric and neonatal patients using fewer blood samples. That experience complemented her broader investigation of populations whose dosing needs may be difficult to capture through standard approaches. USCIS approved her I-140 petition under the EB-2 National Interest Waiver category, supporting her continued pursuit of more informative drug models and evidence-based dosing strategies.
